Senzagen AB

Senzagen AB is a biotech company that specializes in developing innovative non-animal test methods for assessing chemical safety. The primary function of Senzagen is to provide alternative testing solutions that replace traditional animal testing in the cosmetics, pharmaceutical, and chemical industries. The company's flagship product, GARD (Genomic Allergen Rapid Detection), uses genomics technology to deliver precise and reliable results for skin sensitization tests. With a strong focus on sustainability and ethics, Senzagen's methods are designed to meet regulatory and consumer demands for cruelty-free testing practices. By employing proprietary genomic technologies, the company ensures high accuracy and reproducibility in testing, offering a humane and effective alternative to animal testing. Senzagen's solutions have gained traction in Europe and globally, reflecting a shift towards ethical testing methods across the industry. The company plays a critical role within the biotech sphere, influencing how safety assessments are conducted in various sectors, and marking significant progress in achieving the EU's vision for a future without animal testing. Headquartered in Lund, Sweden, Senzagen is at the forefront of redefining standards in chemical safety evaluations.